Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

Oct 29, 2009

Protox Therapeutics Inc., a leader in the development of receptor targeted fusion proteins, today announced that detailed data from its open-label Phase 2 clinical study of PRX302 in patients with moderate to severe benign... [read full story]

Add Comment

View all news articles about*:

Health Hyperplasia Male Prostatic

*Newstin tag cloud displays all featured persons, associated organizations, related topics, regions and companies

Send to a friend | Bookmark with

NewstinMap

Click to Open NewstinMap —

Visual Navigation

My Newstin

Context

Male Health
Prostatic Hyperplasia

Intelligent Data Fusion

About Us

Visit our corporate homepage to learn more about our company and products.

Protox Therapeutics to present Phase 2 study data of PRX302 for benign prostatic hyperplasia

View other selected articles:

Carbon Monoxide Risk Prompts Gas Range Recall

5 Thankful Thoughts About Your Body Image

World AIDS Day Observance at The Belcourt

International Editions